CERC-301

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CERC-301
CERC-301.svg
Names
IUPAC name
4-Methylbenzyl (3S,4R)-3-fluoro-4-[(2-pyrimidinylamino)methyl]-1-piperidinecarboxylate
Identifiers
ChemSpider 9569140
Jmol-3D images Image
PubChem 11394238
Properties
C19H23FN4O2
Molar mass 358.41 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD).[1] In November 2013, phase II clinical trials were initiated,[2] and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.[3]

A pilot study was published in 2012,[1] and a phase 2 trial was completed in 2014.[4]

See also[edit]

References[edit]

External links[edit]